

Notification of Major Holdings

1. Details of issuer

Name:	Heidelberg Pharma AG
Street:	Gregor-Mendel-Str. 22
Postal code:	68526
City:	Ladenburg
	Germany
Legal Entity Identifier (LEI):	391200E09XYBYITR1W32

2. Reason for notification

	Acquisition/disposal of shares with voting rights	1
Х	Acquisition/disposal of instruments	
	Change of breakdown of voting rights	
	Other reason:	1
	Conclusion of a pool agreement	

3. Details of person subject to the notification obligation

Natural person (first name, surname): Friedrich von Bohlen und Halbach Date of birth: 29 Jun 1962

Names of shareholder(s)

```
holding directly 3% or more voting rights, if different from 3.
dievini Hopp BioTech holding GmbH & Co. KG
DH-LT-Investments GmbH
```

5. Date on which threshold was crossed or reached:

13 March 2022

6. Total positions

	% of voting rights	% of voting rights	Total of	Total number of voting
	attached to shares	through instruments	both in %	rights pursuant to Sec.
	(total of 7.a.)	(total of 7.b.1 +	(7.a. +	41 WpHG
		7.b.2)	7.b.)	
New	28.69 %	2.53 %	28.69 %	34175809
Previous	n/a %	n/a %	n/a %	/
notification				

7. Details on total positions

a. Voting rights attached to shares (Sec. 33, 34 WpHG)

ISIN	Abso	lute	In	00
	DirectIndirect(Sec. 33 WpHG)(Sec. 34 WpHG)		Direct	Indirect
			(Sec. 33 WpHG)	(Sec. 34 WpHG)
DE000A11QVV0	0	9803357	0.00 %	28.69 %
Total	9803	3357	28.6	59 %

1	b.1.	Instruments	according to Sec. 38	(1) no. 1 WpHG		
	Туре	of	Expiration or	Exercise or conversion	Voting rights	Voting rights
	instr	rument	maturity date	period	absolute	in %

					0	0.00 %		
		Total			0	0.00 %		
b.2. Instruments	b.2. Instruments according to Sec. 38 (1) no. 2 WpHG							
Type of	Expiration or	Exercise or	Cash or ph	ysical	Voting rights	Voting		
instrument	maturity date	conversion period	settlement		absolute	rights in		
						90		
Share transfer	n/a	n/a	n/a		864120	2.53 %		
agreement								
			Total		864120	2.53 %		

8. Information in relation to the person subject to the notification obligation

Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).

X Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name	% of voting rights	% of voting rights through	Total of both (if
	(if at least 3% or	instruments (if at least 5% or	at least 5% or
	more)	more)	more)
-Friedrich von	90	8	8
Bohlen und Halbach			
-Bohlini invest	28.69 %	8	28.69 %
GmbH			

9. In case of proxy voting according to Sec. 34 para. 3 WpHG

(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:

Hold	ling	total	positions	after	general	meeting	(6.)	after	annual	general	meeting:	
												-

Proportion of voting rights	Proportion of instruments	Total of both
<u>%</u>	8	90

10. Other explanatory remarks:

Accession of Bohlini invest GmbH to the pool agreement between dievini Hopp BioTech holding GmbH & Co. KG, DH-LT-Investments GmbH, MH-LT-Investments GmbH. The instruments specified under 7.b.2 relate to voting rights shares which are already attributed to Bohlini invest GmbH by joining the pool agreement (7.a); therefore, no addition is made under 6. (Total voting rights) no addition of the sum 7.a + 7.b.

Date

14 March 2022

17.03.2022 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language:	English	
Company:	Heidelberg Pharma AG	
	Gregor-Mendel-Str. 22 68526 Ladenburg	
	Germany	
Internet:	www.heidelberg-pharma.com	
End of News	DGAP News Service	

DGAP - ein Service der EQS Group AG Twitter | Impressum | AGB | Datenschutzhinweise | Cookie-Richtlinie